15-05-2025
Agios Pharma (AGIO) Gets a Buy from Bank of America Securities
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Agios Pharma (AGIO – Research Report) yesterday and set a price target of $52.00. The company's shares closed yesterday at $28.03.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Stranahan covers the Healthcare sector, focusing on stocks such as Beam Therapeutics, Candel Therapeutics, and Novavax. According to TipRanks, Stranahan has an average return of -12.1% and a 34.60% success rate on recommended stocks.
In addition to Bank of America Securities, Agios Pharma also received a Buy from Cantor Fitzgerald's Eric Schmidt FCA in a report issued on May 13. However, on May 2, Leerink Partners maintained a Hold rating on Agios Pharma (NASDAQ: AGIO).
Based on Agios Pharma's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $8.73 million and a GAAP net loss of $89.29 million. In comparison, last year the company earned a revenue of $8.19 million and had a GAAP net loss of $81.55 million
